MOv18 IgE

Cancer Research UK · Phase 1 active Small molecule

At a glance

Generic name	MOv18 IgE
Sponsor	Cancer Research UK
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer (PHASE1)
Phase I Study of MOv18 IgE (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MOv18 IgE CI brief — competitive landscape report
MOv18 IgE updates RSS · CI watch RSS
Cancer Research UK portfolio CI